RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and Sofinnova
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase